The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has cleared an investigational new drug utility from Scancell Holdings plc for a registrational section...
The U.S. Meals and Drug Administration (FDA) has accepted a supplemental biologics license utility and granted precedence evaluation for Datroway (datopotamab deruxtecan)...
